<DOC>
	<DOCNO>NCT00849186</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving sunitinib surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This clinical trial study side effect give sunitinib surgery see well work treat patient localize metastatic kidney cancer .</brief_summary>
	<brief_title>Sunitinib Surgery Treating Patients With Localized Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety sunitinib malate patient localize metastatic renal cell carcinoma . - Determine safety surgery 90 day treatment sunitinib malate patient . Secondary - Determine response patient 90 day treatment sunitinib malate . OUTLINE : Patients receive oral sunitinib malate daily day 1-90 absence disease progression unacceptable toxicity . Patients undergo radical nephrectomy . After completion study treatment , patient follow 3 month .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose renal cell carcinoma Clinical stage T1b , T2 , T3 tumor without nodal hematogenous metastasis Localized metastatic disease renal biopsy Primary tumor must amenable surgical removal No history know spinal cord compression carcinomatous meningitis OR evidence symptomatic brain leptomeningeal disease CT scan MRI Treated , stable , asymptomatic brain metastasis allow PATIENT CHARACTERISTICS : ECOG performance status 01 ANC ≥ 1,500/mm^3 Platelets ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5 time ULN liver function abnormality due underlying malignancy ) Total bilirubin ≤ 1.5 time ULN Creatinine &lt; 2 mg/dL OR creatinine clearance &gt; 40 mL/min Calcium ≤ 10.2 mg/dL QTc interval &lt; 500 msec Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 ( male ) 6 ( female ) month completion study treatment No serious intercurrent illness include , limited , follow : Clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension , myocardial infarction , unstable angina ) New York Heart Association ≥ class II congestive heart failure Serious cardiac arrhythmia require medication Peripheral vascular disease ≥ grade 2 Psychiatric illness/social situation would limit compliance study requirement None follow condition within past 6 month : Myocardial infarction Severe/unstable angina Coronary/peripheral artery bypass graft Symptomatic congestive heart failure Cerebrovascular accident transient ischemic attack Pulmonary embolism No ongoing cardiac dysrhythmias NCI CTCAE version 3.0 ≥ grade 2 No hypertension control medication ( i.e. , diastolic blood pressure &gt; 100 mm Hg despite optimal medical therapy ) No know HIV positivity PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>stage I renal cell cancer</keyword>
	<keyword>stage II renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>